CV Sciences ( (CVSI) ) has released its Q2 earnings. Here is a breakdown of the information CV Sciences presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CV Sciences, Inc. is a consumer wellness company that specializes in hemp extracts and other science-backed, natural ingredients and products, operating primarily in the nutraceutical and plant-based food sectors. The company is known for its +PlusCBD™ branded products, which are leading in the natural products market.
In its second quarter of 2025 financial results, CV Sciences reported a revenue of $3.6 million, which is consistent with the first quarter of 2025 but represents a decrease from the $4.0 million reported in the same quarter of the previous year. Despite the revenue decline, the company achieved its highest gross margin since 2019 at 50.9%, and reported a positive adjusted EBITDA of $0.1 million, marking a significant turnaround from previous losses.
Key financial highlights include a cash balance increase to $0.9 million from $0.5 million at the end of 2024, and a reduction in operating loss to $0.1 million compared to $0.6 million in the second quarter of 2024. The company attributes these improvements to reduced selling, general, and administrative expenses, as well as strategic efforts in product development and mergers and acquisitions.
CV Sciences is focusing on organic growth through new product development and is actively pursuing additional M&A opportunities to enhance revenue, profitability, and cash flow. The acquisition of Elevated Softgels is expected to improve gross margins further by in-sourcing production of many current products.
Looking forward, CV Sciences remains committed to innovation and diversification of its product offerings to navigate regulatory challenges in the CBD category. The company anticipates continued improvements in gross margins and aims for a balanced product portfolio to drive revenue growth and shareholder value.